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To identify new protein and pharmacological regula-
tors ofWnt/b-catenin signaling, we used a cell-based
reporter assay to screen a collection of 1857 human-
experienced compounds for their ability to enhance
activation of the b-catenin reporter by a low concen-
tration of WNT3A. This identified 44 unique
compounds, including the FDA-approved drug rilu-
zole, which is presently in clinical trials for treating
melanoma. We found that treating melanoma cells
with riluzole in vitro enhances the ability of WNT3A
to regulate gene expression, to promote pigmenta-
tion, and to decrease cell proliferation. Furthermore
riluzole, like WNT3A, decreases metastases in
a mouse melanoma model. Interestingly, siRNAs tar-
geting the metabotropic glutamate receptor, GRM1,
a reported indirect target of riluzole, enhance b-cat-
enin signaling. The unexpected regulation of b-cate-
nin signaling by both riluzole and GRM1 has implica-
tions for the future uses of this drug.
INTRODUCTION
Wnt proteins act as ligands for members of the Frizzled family of
serpentine receptors and for the LRP5/6 coreceptors. Activation
of the pathway results in b-catenin (CTNNB1) stabilization and
nuclear accumulation. Aberrant Wnt/b-catenin signaling arising
from either hyper- or hypoactivation has been linked to
numerous clinical conditions, most notably cancers (Moon
et al., 2004). Several types of cancer have been linked to muta-
tions in core Wnt/b-catenin pathway genes that result in consti-
tutive ligand-independent activation of the pathway (Moon et al.,
2004). However, as described below for melanoma, elevation of
Wnt/b-catenin signaling correlates with or may promote favor-
able biological or clinical outcomes.Chemistry & Biology 17, 1177–118Wnt/b-catenin signaling is a major regulator of melanocyte
differentiation (Thomas and Erickson, 2008), so it is not surprising
that this pathway is also involved in the pathogenesis of malig-
nant melanoma. In a mouse model of malignant melanoma,
Wnt/b-catenin signaling itself is insufficient for melanocyte trans-
formation, but activation of this pathway can work synergistically
with active Ras signaling to promote tumor formation (Delmas
et al., 2007). By contrast, several studies using patient-derived
tumor samples have reported that melanoma progression is
associated with the loss of nuclear b-catenin, a clinical marker
of Wnt/b-catenin activation. Furthermore, improved survival is
seen in patients with higher levels of cytosolic or nuclear b-cate-
nin (Bachmann et al., 2005; Chien et al., 2009; Kageshita et al.,
2001; Maelandsmo et al., 2003), suggesting that active Wnt/b-
catenin signaling in patients predicts improved prognosis. Inter-
estingly, activation of Wnt/b-catenin signaling by Wnt3a in
a mouse melanoma model results in decreased proliferation
in vitro and in vivo, along with increased expression of melano-
cyte differentiation markers usually lost with melanoma progres-
sion, pointing to potential mechanisms that might explain the
improved prognosis of patients with elevated b-catenin (Chien
et al., 2009). Collectively, these observations underscore the
potential importance of determining whether any existing
approved drugs enhance Wnt/b-catenin signaling and whether
they may have therapeutic benefit in treating melanoma.
In the present study, we used a cell-based screen to identify
several small molecule enhancers of Wnt/b-catenin signaling. We
focused on one enhancer compound, riluzole, an FDA approved
therapeutic for amyotrophic lateral sclerosis that is under investi-
gation in clinical trials as a melanoma therapy (Yip et al., 2009).RESULTS AND DISCUSSION
Using the b-catenin-activated luciferase reporter (BAR) (Biechele
andMoon, 2008) (see Figure S1A available online) in a cell-based
assay, we screened for small molecules that enhance the activa-
tion of the reporter by exogenous WNT3A (Figure 1 inset). We
optimized the WNT3A stimulus to obtain an EC20 (Figure S1B)2, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1177
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Figure 1. Chemical Screen Identifies Human-Experienced Small Molecule Enhancers of Wnt/b-Catenin Signaling
(A) A human-experienced collection of chemicals was screened in HT22 cells stably expressing BAR for enhancers of Wnt/b-catenin signaling.
(B)Histogram representation of flowcytometric analysis of A375melanomacells stably expressing theBAR-Venus reporter in theabsence andpresence ofWNT3A.
(C) A375:BAR-Venus cells were treated with control conditioned media (CM) or WNT3A CM and sorted for Venus-positive and -negative based on a gate set by
A375 cells stably expressing a control reporter (fuBAR-Venus). AXIN2 and TNFRSF19 expression was determined by qRT-PCR.
(D) Cells were treated with 10 mM of each compound (100 mM alendronate) for 18 hr, harvested, and analyzed by flow cytometry.
(E) A375 melanoma cells transiently transfected with BAR were treated with WNT3A CM and DMSO or riluzole at the indicated doses.
In (D) and (E) Data represent the mean value of triplicate experiments ± SDd. *p < 0.003, **p < 0.0002. See also Figure S1.
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Riluzole Enhances Wnt/b-Catenin Signalingin HT22 neuronal cells and screened a library of 1857 human
experienced chemicals (1500 unique). We identified 47 (44
unique) chemicals that enhanced the WNT3A stimulus greater
than 1.5-fold (Figure 1A; Supplemental Database), several of
which displayed a dose-dependent enhancement of Wnt/b-cat-
enin signaling upon rescreening (Figures S1C and S1E).1178 Chemistry & Biology 17, 1177–1182, November 24, 2010 ª2010To rule out the formal possibility that some of the primary hits
from the screen act directly on luciferase activity rather than on
the Wnt/b-catenin pathway, we used a second cell-based
Wnt/b-catenin reporter system in which Venus fluorescent
protein is the reporter gene (Rekas et al., 2002). WNT3A stimula-
tion of cells stably expressing this reporter promoted an increaseElsevier Ltd All rights reserved
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Riluzole Enhances Wnt/b-Catenin Signalingin both the number of Venus positive cells and their mean fluo-
rescent intensity (MFI) by FACS analysis (Figure 1B). To validate
that Venus expression is tightly linked to b-catenin signaling, the
expression of endogenous b-catenin target genes in Venus-
positive and -negative cells was compared. Consistent with
a positive correlation, the Venus-positive population of untreated
cells, or the Venus-positive population of cells that had been
treated with WNT3A-conditioned media prior to FACS sorting,
showed elevated expression of the b-catenin target genes
AXIN2 and TNFRSF19 when compared with Venus-negative
cells (Figure 1C). In this assay, several primary screen hits
enhanced the WNT3A-mediated increase in the percentage of
Venus-positive cells and their MFI (Figure 1D).
Candidate hits from the primary screen were analyzed with
respect to their being mentioned in the literature and in clinical
trials databases, enabling us to generate a list of diseases where
these bioactive molecules were being studied. We compared
this list to the diseases being treated with lithium chloride,
a classic inhibitor of GSK3 which is the only available patient-
experienced drug that is known to activate Wnt/b-catenin
signaling. As a result of this analysis, we focused on the drug
riluzole (brand name Rilutek) (Figure S1D), an FDA-approved
drug used to slow the progression of amyotrophic lateral scle-
rosis (ALS) (Aggarwal and Cudkowicz, 2008). Riluzole is under
intensive evaluation as a treatment for bipolar disorder, a condi-
tion where lithium chloride is a first-line treatment (Pittenger
et al., 2008). Lithium is also being evaluated as a treatment for
ALS (Fornai et al., 2008), which is also consistent with the possi-
bility that these two unrelated compounds may regulate the
same signaling pathway(s).
Riluzole enhancedWnt/b-catenin signaling in both the primary
screen in HT22 neuronal cells (Figure S1E) and in adult hippo-
campal progenitor cells (Figure S1F). Furthermore, riluzole
enhanced the stabilization and nuclear localization of b-catenin
in U2OS cells (Figures S2A and S2B). As riluzole is in clinical trials
for treatment of metastatic melanoma (Yip et al., 2009) and
decreased Wnt/ b-catenin in clinical samples has been associ-
ated with melanoma progression (Chien et al., 2009), we focused
on validating this hit and investigating its mechanism of action in
the context of melanoma. We first demonstrated that riluzole
enhances Wnt/b-catenin signaling in a dose-dependent manner
in A375 melanoma cells stably expressing BAR confirming the
observations in neuronal cells (Figure S2C). As a control, we
showed that riluzole does not activate a control reporter
construct (fuBAR) in which the TCF/LEF sites required for re-
sponding to b-catenin have been mutated (Figure S2C). We
next demonstrated that riluzole enhances the WNT3A-depen-
dent activation of the promoter of a known direct target gene
of b-catenin, Axin2 (Figure 1E). Moreover, riluzole, like WNT3A,
upregulates several genes involved in melanocyte development
(Trpm1, Met, Mitf, Sox9, Kit, and Si) alone (Figure 2A) and in
synergy with exogenous WNT3A (Figure 2B).
Consistent with the reported ability of WNT3A to elevate levels
of transcripts involved in melanocyte differentiation (Chien et al.,
2009), treating B16melanoma cells withWNT3A leads to a dose-
and b-catenin-dependent increase in cellular pigmentation (Fig-
ure 2C; Figure S2D). Treatment of these cells with riluzole also
increases pigmentation, and does so in a b-catenin-dependent
manner that is synergistically enhanced by cotreatment withChemistry & Biology 17, 1177–118WNT3A (Figure 2C; Figure S2D). Analysis of riluzole-treated
B16 cells in which siRNAs have been used to deplete endoge-
nous b-catenin showed that Wnt-3a and riluzole synergize in
a b-catenin-dependent manner to elevate the expression of
Trpm1 (Figure 2D).
We have previously demonstrated that elevated Wnt/b-cate-
nin signaling in melanoma cell lines cultured in vitro, and in mela-
noma patients, correlates with a reduction in cell proliferation
(Chien et al., 2009), raising the question as to whether riluzole
would also affect proliferation. Synergy between riluzole and
WNT3A was observed in the reduction of proliferation in B16
cells (Figure 2E).We also observed a decrease in the proliferation
of several human melanoma cell lines in the presence of riluzole
(Figure S2E).
We then tested whether riluzole inhibits melanoma progres-
sion in vivo using B16 melanoma cells implanted into the foot-
pads of mice, followed by treating the mice with riluzole. There
was a striking reduction in metastases compared with vehicle-
treated mice, as measured by the detection of cells in the
sentinel popliteal lymph node (Figure 2F). Collectively, the data
show that riluzole both mimics and enhances the ability of
WNT3A to promote differentiation of melanoma cells toward
amoremelanocyte-like state, that riluzole decreases the prolifer-
ation of melanoma cells in vitro, and that riluzole reduces the
metastasis of melanoma cells in vivo.
To better understand the mechanism by which riluzole
enhances Wnt/b-catenin signaling in melanoma cells, we
explored knownsignaling targets andpathwayspreviously linked
to riluzole. In a phase 0 trial of riluzole for treatment of melanoma,
it was shown that tumors from patients treated with riluzole
exhibited decreased phosphorylation of ERK (Yip et al., 2009).
However, treatment of A375 human melanoma cells with riluzole
resulted in no change in ERK phosphorylation (Figure S3A).
Another possible mechanism for riluzole to enhanceWnt/b-cate-
nin signaling involves the activation of PKA through a riluzole-
mediated increase in cAMP levels (Duprat et al., 2000; Taurin
et al., 2006). To test this mechanism, A375 cells were treated
with riluzole or with forskolin, a small molecule known to activate
adenylyl cyclase and thus PKA (Seamon et al., 1981). Cell lysates
from forskolin, but not riluzole-treated cells, showed a significant
enhancement in PKA-phosphorylated CTNNB1 as well as other
protein substrates relative to controls (Figure S3B).
Previously, a mouse with a high incidence of spontaneous
melanoma-like lesions was found to carry a mutation that led
to elevated expression of metabotropic glutamate receptor 1
(GRM1) (Pollock et al., 2003). Riluzole has been reported to
inhibit glutamate release and reuptake and thereby inhibit activa-
tion of metabotropic glutamate receptors (Doble, 1996). If rilu-
zole enhances Wnt/b-catenin signaling through a mechanism
involving GRM1 then reducing GRM1 expression might enhance
Wnt/b-catenin signaling. To test this hypothesis, we transfected
A375:BAR melanoma cells with two independent siRNAs target-
ing GRM1, or with siRNAs targeting CTNNB and AXIN1/2 as
controls. Both GRM1 siRNAs depleted GRM1 transcript levels
to approximately 10% of control siRNA transfected cells (Fig-
ure S3C). Strikingly, reduction of GRM1 transcripts by siRNAs
synergized with WNT3A in the BAR luciferase reporter assay,
demonstrating that endogenous GRM1 functionally represses
Wnt/b-catenin signaling (Figure 3A). GRM1-directed siRNAs2, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1179
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Figure 2. Riluzole Enhances Wnt/b-Catenin
Signaling to Promote Markers of Differenti-
ation and Decrease the Proliferation of
Melanoma Cells
(A) B16 melanoma cells were treated with 10 mM
riluzole or DMSO for 24 hr and qRT-PCR was per-
formed. All data were normalized to Gapdh
expression and represent the mean value of tripli-
cate experiments ± SD.
(B) B16 melanoma cells were treated with a low
dose of WNT3A conditioned media and DMSO or
the indicated doses of riluzole for 6 hr and profiled
for the expression of Axin2, Si/gp100, and Kit by
qRT-PCR. All data were normalized to gapdh
expression, expressed as fold over the corre-
sponding DMSO control, and represent the mean
value of triplicate experiments ± SD.
(C and D) B16 melanoma cells transfected with
control or Ctnnb1 siRNA were treated for 3 days
with the indicated conditions and analyzed for
pigmentation (C) and Trpm1 expression (D). The
pigmentation data are representative of three inde-
pendent experiments andTrpm1 expression repre-
sents themean valueof triplicate experiments ±SD.
(E) Riluzole synergizeswithWNT3A to decrease the
proliferation of melanoma cells. B16 cells were
treated for 4 days in the indicated conditions and
then harvested and counted. Data represent the
mean value of six experiments ±SD.
(F)B16cellswere injected into footpadsofC57BL/6
mice, and treatment with riluzole was initiated
1 week postinjection. Sentinel lymph nodes in the
popliteal fossa adjacent to the injected foot were
assayed for the presence of metastases as
measured by Firefly luciferase.
Bars represent the mean and standard deviation of
ten mice for each group and indicate that tumors
from mice treated with riluzole exhibited signifi-
cantly decreased metastasis compared to control
mice with no treatment (unpaired two-tailed t test)
*p < 0.02. See also Figure S2.
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Riluzole Enhances Wnt/b-Catenin Signalingalso enhanced WNT3A-mediated upregulation of endogenous
AXIN2 transcripts (Figure S3D). Consistent with these findings,
three structurally unrelated GRM1-selective small molecule
antagonists enhanced WNT3A-stimulated BAR activity in
A375:BAR cells in a dose-dependent manner (Figure 3B).
Furthermore, like riluzole, all three GRM1-selective antagonists
enhance the pigmentation of B16 melanoma cells alone and
synergize with WNT3A (Figures 3C and 3D; Table S1), while
antagonists of the related glutamate receptor, GRM5, have no
effect on BAR activity or B16 melanoma cell pigmentation
(Figure S3E and Table S1). Collectively, these data identify
GRM1 and not GRM5 as a novel regulator of Wnt/b-catenin
signaling and the likely target of riluzole-mediated enhancement
of Wnt/b-catenin signaling.
SIGNIFICANCE
This article describes the identification and characterization
of the FDA-approved drug riluzole as an enhancer of
Wnt/b-catenin signaling in melanoma cells. In melanoma
cells, riluzole enhances the ability of WNT3A to regulate
gene expression, to promote pigmentation, and to decrease1180 Chemistry & Biology 17, 1177–1182, November 24, 2010 ª2010proliferation. Furthermore, riluzole, like WNT3A, decreased
metastases in vivo in a mouse melanoma model. Investi-
gating the mechanisms of action of riluzole revealed that
endogenous metabotropic glutamate receptor GRM1 but
not GMR5 represses Wnt-mediated activation of b-catenin
signaling in melanoma cells. Given that riluzole is in clinical
trials for treatingmelanoma, our data that riluzolemodulates
b-catenin signaling, combined with prior data that b-catenin
signaling has complex effects in different cancers, should
stimulate further investigation into the use of riluzole in
cancer therapies.
EXPERIMENTAL PROCEDURES
Full details of materials and experimental procedures used in this study can be
found in the Supplemental Experimental Procedures that accompany this Brief
Communication (available online).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Database, three figures, and two tables and can be found
with this article online at doi:10.1016/j.chembiol.2010.08.012.Elsevier Ltd All rights reserved
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Figure 3. GRM1 Negatively Regulates Wnt/
b-Catenin Signaling
(A) siRNA mediated knockdown of GRM1
enhances Wnt/b-catenin signaling in melanoma
cells.
(B) A375:BAR cells were treated with WNT3A CM
and several doses of riluzole (1, 5, 10, 20 mM),
A841720 (0.1, 1, 10, 20 mM), LY456236 (0.1, 1,
10, 20 mM), or Bay 36-7620 (0.5, 1, 5, 10 mM).
(C and D) B16 melanoma cells were treated for
3 days with the indicated conditions. Riluzole
andBay 36-7620were used at 10 mMfinal concen-
tration. Cells were trypsinized and pelleted for
imaging (C) followed by resuspension and
405 nm absorbance measurement (D).
In (A), (B), and (D), data represent the mean value
of triplicate experiments ±SD. In (C), data are
representative of three independent experiments.
See also Figure S3.
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